Patient P-02108
Synthetic patientMETA-24 · Day 178 · 55–64 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
66%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 19 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 67 SC-12 recommended — Supportive Compound SC-12
- Day 68 Patient accepted — Started SC-12 in the companion
- Day 74 GI symptom burden −14% vs expected — Supportive Compound SC-12
- Day 80 Tolerance state changed — Unstable → Improving
- Day 81 GI-04 recommended — GI Support Protocol GI-04
- Day 82 Patient accepted — Started GI-04 in the companion
- Day 90 GI symptom burden −36% vs expected — GI Support Protocol GI-04
- Day 96 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 19.
Primary contributors, last 14 days
- Inflammatory activity-11
- Treatment adherence+7
- Toxicity-7
- GI instability+3
What helped?
- Supportive Compound SC-12Day 67Result: symptom burden −14%
- GI Support Protocol GI-04Day 81Result: symptom burden −36%
LIFE OS recommendation
Monitoring Escalation ME-01
83%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable21 min
worsening · -8.1 vs previous 14 d
Sleep duration
Wearable6.5 h
stable · -0.1 vs previous 14 d
Energy level
Daily log3.4/10
worsening · -0.4 vs previous 14 d
Steps
Wearable3,158
worsening · -632 vs previous 14 d
GI burden
Companion48.2/100
worsening · +12.2 vs previous 14 d
Adherence
Companion53.4 %
stable · -0.3 vs previous 14 d
Sleep quality
Wearable32.2/100
worsening · -3.6 vs previous 14 d
Glucose, CGM daily mean
CGM135 mg/dL
stable · +2.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 35 from the failing basin, 52 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 41 similar · onset 3 d · confidence 71%
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 71%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 71%
- More proteinGI -4.7 next day on high-intake days · n 24
Would not help
- Keep ultra-processed lowGI +4.5 next day on high-intake days · n 24
- Keep fat lowGI +4 next day on high-intake days · n 13
- Keep alcohol lowGI +3.6 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.7supporter · 95%
- Ultra-processed food+4.5detractor · 95%
- Dietary fat load+4detractor · 95%
- Alcohol+3.6detractor · 95%
- Caffeine+3detractor · 95%
- Histamine load+2.9detractor · 95%
- Insoluble fibre+1.8no signal · 50%
- Simple carbohydrates+1.6no signal · 41%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 46
- WearableHRV 32 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 24/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 43
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 48 and rising
- Autonomic recovery ↑45
- WearableResting HR 72 bpm
- Wearable3,158 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.1 · butyrate capacity 24/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 33 ms
- Sleep
- 5.8 h
- Steps
- 3,808
- Resting HR
- 73 bpm
Daily log: GI score 48, nutritional resilience 45, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.